Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 19930611)

  • 1. Routine use of ancillary investigations in staging diffuse large B-cell lymphoma improves the International Prognostic Index (IPI).
    Talaulikar D; Shadbolt B; Dahlstrom JE; McDonald A
    J Hematol Oncol; 2009 Nov; 2():49. PubMed ID: 19930611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Staging bone marrow in diffuse large B-cell lymphoma: the role of ancillary investigations.
    Talaulikar D; Dahlstrom JE
    Pathology; 2009; 41(3):214-22. PubMed ID: 19291532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Precision of histological bone marrow staging in follicular lymphoma and diffuse large B-cell lymphoma.
    Chen T; McDonald A; Shadbolt B; Talaulikar D
    Clin Invest Med; 2012 Dec; 35(6):E358-64. PubMed ID: 23217561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Occult bone marrow involvement in patients with diffuse large B-cell lymphoma: results of a pilot study.
    Talaulikar D; Dahlstrom JE; Shadbolt B; McNiven M; Broomfield A; Pidcock M
    Pathology; 2007 Dec; 39(6):580-5. PubMed ID: 18027262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of immunohistochemistry in staging diffuse large B-cell lymphoma (DLBCL).
    Talaulikar D; Dahlstrom JE; Shadbolt B; Broomfield A; McDonald A
    J Histochem Cytochem; 2008 Oct; 56(10):893-900. PubMed ID: 18574254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
    Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
    Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical role of flow cytometry in redefining bone marrow involvement in diffuse large B-cell lymphoma (DLBCL) - a new perspective.
    Talaulikar D; Shadbolt B; Bell J; Khan K; Dahlstrom JE; McDonald A; Pidcock M; Broomfield A
    Histopathology; 2008 Feb; 52(3):340-7. PubMed ID: 18269585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The clinical characteristics of 681 patients with diffuse large B-cell lymphoma].
    Wen JJ; Liu ZB; Xu J; Xu CG
    Zhonghua Xue Ye Xue Za Zhi; 2012 Dec; 33(12):1004-9. PubMed ID: 23363791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of Bone Marrow Biopsy and Aspirate for Staging of Diffuse Large B Cell Lymphoma in the Era of Positron Emission Tomography With 2-Deoxy-2-[Fluorine-18]fluoro-deoxyglucose Integrated With Computed Tomography.
    Vishnu P; Wingerson A; Lee M; Mandelson MT; Aboulafia DM
    Clin Lymphoma Myeloma Leuk; 2017 Oct; 17(10):631-636. PubMed ID: 28684378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of infiltrating immune cells within bone marrow of patients with diffuse large B-cell lymphoma.
    Jeong J; Oh EJ; Yang WI; Kim SJ; Yoon SO
    Hum Pathol; 2017 Jun; 64():222-231. PubMed ID: 28438619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD5 positivity is an independent adverse prognostic factor in elderly patients with diffuse large B cell lymphoma.
    Chuang WY; Chang H; Shih LY; Wang PN; Chang YS; Lin TL; Hung YS; Yeh CJ; Ueng SH; Tang TC; Kuo MC; Dunn P; Wu JH; Kao HW; Ou CW; Wan YL; Hsueh C
    Virchows Arch; 2015 Nov; 467(5):571-82. PubMed ID: 26369546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can flow cytometry of bone marrow aspirate predict outcome of patients with diffuse large B cell lymphoma? A retrospective single centre study.
    Wolach O; Fraser A; Luchiansky M; Shapiro C; Radnay J; Shpilberg O; Lishner M; Lahav M
    Hematol Oncol; 2015 Mar; 33(1):42-7. PubMed ID: 24470400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of concordant and discordant bone marrow involvement and cell-of-origin in Korean patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Park MJ; Park SH; Park PW; Seo YH; Kim KH; Seo JY; Jeong JH; Kim MJ; Ahn JY; Hong J
    J Clin Pathol; 2015 Sep; 68(9):733-8. PubMed ID: 25998512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low levels of monoclonal small B cells in the bone marrow of patients with diffuse large B-cell lymphoma of activated B-cell type but not of germinal center B-cell type.
    Tierens AM; Holte H; Warsame A; Ikonomou IM; Wang J; Chan WC; Delabie J
    Haematologica; 2010 Aug; 95(8):1334-41. PubMed ID: 20145271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
    Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
    J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cd20 Expression and Effects on Outcome of Relapsed/ Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab.
    Rasheed AA; Samad A; Raheem A; Hirani SI; Shabbir- Moosajee M
    Asian Pac J Cancer Prev; 2018 Feb; 19(2):331-335. PubMed ID: 29479962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [T-cell/histiocyte-rich B-cell lymphoma: histology, immunophenotype and differential diagnosis].
    Liu YH; Zhuang HG; Lin HL; Wu QL; Luo DL; Luo XL
    Zhonghua Bing Li Xue Za Zhi; 2005 Dec; 34(12):771-5. PubMed ID: 16545182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of the immunophenotype versus the International Prognostic Index in aggressive non-Hodgkin's lymphoma.
    Intragumtornchai T; Rotnakkarin P; Sutcharitchan P; Wannagrairoj P
    Clin Lymphoma; 2003 Jun; 4(1):52-5. PubMed ID: 12837156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Standardized uptake value for (18)F-fluorodeoxyglucose is correlated with a high International Prognostic Index and the presence of extranodal involvement in patients with diffuse large B-cell lymphoma.
    Akkas BE; Vural GU
    Rev Esp Med Nucl Imagen Mol; 2014; 33(3):148-52. PubMed ID: 24094371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma.
    El-Galaly TC; Villa D; Alzahrani M; Hansen JW; Sehn LH; Wilson D; de Nully Brown P; Loft A; Iyer V; Johnsen HE; Savage KJ; Connors JM; Hutchings M
    Am J Hematol; 2015 Nov; 90(11):1041-6. PubMed ID: 26260224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.